Stellar Presents Preclinical Poster on C. diff Active Immunotherapy
Complete the form below to unlock access to ALL audio articles.
Stellar Biotechnologies, Inc. has announced the presentation of a preclinical poster at the 7th Vaccine and ISV Congress being held in Sitges, Spain, October 27-29, 2013.
The presentation relates to a recent study in mice of Stellar’s newly acquired active immunotherapy technology targeting the treatment of Clostridium difficile infection (“C. diff”).
Clostridium difficile is a bacteria found in the intestines that can cause severe and life-threatening intestinal conditions. C. diff infections are at an all-time high and related hospitalizations have tripled in the last decade.
The poster titled “Immunization with Clostridium difficile PSII Polysaccharide Antigens Adjuvanted with KLH Induced Broad-based Enhancement of Adaptive Immune Responses and Protection in Mice” is the result of preclinical research conducted together by scientists from Stellar and the University of Guelph (Ontario, Canada) (“Guelph”).
In the study, vaccination with a PSII-KLH conjugate vaccine conferred protection against C. diff infection, measured by improved survival rates in vaccinated mice compared to unvaccinated controls.
The study concluded that the C. diff PSII-KLH immunotherapy approach was safe and efficacious in a preclinical model. Further preclinical development is underway.
The 7th Vaccine & ISV Congress features science and public health topics, from primary vaccine research and vaccine manufacturers, to governmental policy, safety and regulation.
